---
schema_version: "secwatch.filing_event.v1"
accession: "0001217234-25-000007"
form_type: "8-K"
ticker: "CDNA"
cik: "0001217234"
company_name: "CareDx, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:23:03.368066+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CareDx Q4 revenue $86.6M (+32% YoY), FY2025 guidance $365-375M; $50M buyback

## Summary
- Q4 revenue $86.6M (+32% YoY); testing services revenue $63.8M (+37%); volume ~45,500 tests (+14%).
- Q4 GAAP net income $87.7M ($1.51 diluted EPS) vs loss $118.1M in Q4 2023; non-GAAP net income $10.7M ($0.18).
- Full year revenue $333.8M (+19%); net income $52.5M (incl. $96.3M litigation reversal); adj. EBITDA $27.8M.
- Board authorized $50M stock buyback over up to 24 months. Cash $261M, no debt as of Dec 31, 2024.
- FY2025 revenue guidance $365M-$375M (9-12% growth); CEO cites 'transformative year' and long-term growth.

## SEC filing metadata
- accession: 0001217234-25-000007
- form_type: 8-K
- ticker: CDNA
- cik: 0001217234
- company_name: CareDx, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1217234/000121723425000007/0001217234-25-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1217234/000121723425000007/cdna-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001217234-25-000007
- JSON: https://secwatch.observer/filing/0001217234-25-000007.json
- Plain text: https://secwatch.observer/filing/0001217234-25-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.